Erschienen in:
01.04.2014 | Review Article
Antiangiogenic therapy of brain tumors: the role of bevacizumab
verfasst von:
Elisa Trevisan, Luca Bertero, Chiara Bosa, Michela Magistrello, Alessia Pellerino, Roberta Rudà, Riccardo Soffietti
Erschienen in:
Neurological Sciences
|
Ausgabe 4/2014
Einloggen, um Zugang zu erhalten
Abstract
Angiogenesis is one of the hallmarks of cancer, including brain tumors. Malignant gliomas have the highest degree of vascular proliferation among solid tumors; thus, angiogenic pathways represent an attractive target to interfere with tumor growth. Up to date VEGF pathway targeting with specific drugs has yielded interesting therapeutics results. In particular bevacizumab, a monoclonal antibody against VEGF-A, has shown clinical activity in malignant gliomas, especially glioblastomas, in terms of a high response rate on MRI and a significant increase in progression-free survival.